BioAgilytix Welcomes Samuel Pine to Leadership Team as Director of Bioanalytical Operations, Europe

Dr. Pine Brings Over 23 Years of Experience Supporting Biotherapeutic, Vaccine, and Immunodiagnostic Drug Development from Discovery Through Post-Marketing

June 19, 2017—Durham, NC and Hamburg, Germany—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has announced the addition of Samuel Pine, Ph.D. to its leadership team as Director of Bioanalytical Operations, Europe. Dr. Pine will oversee work at BioAgilytix’s laboratory in Hamburg, Germany, home to its subsidiary IPM Biotech. He will serve as Test Facility Manager overseeing GxP and non-GxP bioanalytical method development, validation, and sample analysis for large molecule projects, while aligning objectives and resources across bioanalytical teams to ensure consistent quality and timeliness of client deliverables.

Dr. Pine is an accomplished immunologist with an extensive background supporting biotherapeutic, vaccine, and immunodiagnostic projects from discovery through post-marketing. Prior to joining BioAgilytix, Dr. Pine was Associate Director of Non-Clinical and Translational Sciences at Allergan, where he worked closely with drug safety scientists to develop novel protein therapeutics for ocular, neurologic, urologic, and dermatologic indications. He also garnered experience developing vaccines for a variety of infectious diseases through his previous positions with the Infectious Disease Research Institute, the HIV Vaccine Trial Network/Fred Hutchinson Cancer Research Center, and Novartis. Today Dr. Pine holds a patent as the co-inventor of “Composition and methods for stimulating an immune response against infectious agents”, has been published in numerous scientific journals, and actively contributes his insight to regulatory submission documents and peer-reviewed manuscripts.

“Sam is a respected member of the global scientific community and his highly relevant experience will no doubt be invaluable to our European team and to BioAgilytix as a whole,” said Jim Datin, Chief Executive Officer of BioAgilytix. “With his scientific and operational oversight at our newly constructed, state-of-the-art Hamburg facilities, we will only strengthen our ability to deliver best-in-class large molecule bioanalytical services to customers worldwide.”

“I am thrilled to be a part of such a scientifically-driven and customer-focused organization,” said Dr. Pine. “I look forward to applying my experience and perspectives, particularly in vaccinology and in developing immunogenicity methods, to provide guidance to the European team and to help further the world-class research being conducted by BioAgilytix.”

###

About BioAgilytix

BioAgilytix is a leading global bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, GLP, and GCP, as well as product release testing under GMP./p>

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to 23 of the top 25 global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.

Media Contact:
Carla Nieser
Vovéo Marketing Group
610.240.0400, x 118
c.nieser@voveo.com

Share This